Talis Biomedical Corporation (TLIS)

USD 1.6

(6.67%)

Net Debt Summary of Talis Biomedical Corporation

  • Talis Biomedical Corporation's latest annual net debt in 2023 was -57.06 Million USD , up 40.93% from previous year.
  • Talis Biomedical Corporation's latest quarterly net debt in 2024 Q2 was -41.06 Million USD , up 19.63% from previous quarter.
  • Talis Biomedical Corporation reported annual net debt of -96.6 Million USD in 2022, up 55.8% from previous year.
  • Talis Biomedical Corporation reported annual net debt of -218.56 Million USD in 2021, down -58.62% from previous year.
  • Talis Biomedical Corporation reported quarterly net debt of -41.06 Million USD for 2024 Q2, up 19.63% from previous quarter.
  • Talis Biomedical Corporation reported quarterly net debt of -77.81 Million USD for 2023 Q2, up 20.8% from previous quarter.

Annual Net Debt Chart of Talis Biomedical Corporation (2023 - 2018)

Historical Annual Net Debt of Talis Biomedical Corporation (2023 - 2018)

Year Net Debt Net Debt Growth
2023 -57.06 Million USD 40.93%
2022 -96.6 Million USD 55.8%
2021 -218.56 Million USD -58.62%
2020 -137.79 Million USD -537.8%
2019 -21.6 Million USD -213.33%
2018 -6.89 Million USD 0.0%

Peer Net Debt Comparison of Talis Biomedical Corporation

Name Net Debt Net Debt Difference
Acutus Medical, Inc. 12.27 Million USD 564.728%
Biotricity, Inc. 23.09 Million USD 347.108%
Cell MedX Corp. 244.05 Thousand USD 23481.998%
Dynatronics Corporation 6.2 Million USD 1019.789%
Nemaura Medical Inc. 9.92 Million USD 674.951%
PetVivo Holdings, Inc. 1.27 Million USD 4566.37%
RetinalGenix Technologies Inc. 506.53 Thousand USD 11365.581%
Sonendo, Inc. 26.34 Million USD 316.627%
Telesis Bio, Inc. 32.63 Million USD 274.855%
Viveve Medical, Inc. -13.81 Million USD -313.118%